CD4 and rheumatoid arthritis: Treatment indicators of disease activity before and after low-dose IL2 therapy showed a significant decrease; DAS28 (5.44 ± 1.34 vs 3.66 ± 1.09, p < 0.001), TJC (10.07 ± 7.97 vs 3.94 ± 4.76, p < 0.001) and SJC (6.40 ± 7.63 vs 1.70 ± 3.32, p < 0.001). Patients with low-dose IL2 therapy showed a three-fold increase in absolute counts of Treg (26.26 ± 15.51 to 92.80 ± 64.92) and a two-fold increase in CD4+ T cells and its subsets (p < 0.001). Th17/Treg ratio decreased significantly to the level of healthy controls. Low-dose IL2 was tolerated in all patients with RA.